Cover Image

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports

Background: Metabolic effects of integrase strand transfer inhibitors (INSTIs) have been reported. The FDA Adverse Event Reporting System (FAERS) is a publicly available database that captures spontaneously reported adverse events. The objective of this study was to evaluate the relationship between...

Full description

Saved in:

Bibliographic Details
Main Authors:	Milena M Murray (Author), Lara Fakhouri (Author), Spencer E Harpe (Author)
Format:	Book
Published:	BioExcel Publishing Ltd, 2023-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pharmacokinetic drug interactions of integrase strand transfer inhibitors
by: Chi-Hua Lu, et al.
Published: (2021)

HIV-1 Integrase Strand Transfer Inhibitors and Neurodevelopment
by: Emma G. Foster, et al.
Published: (2022)

Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems
by: Han N, et al.
Published: (2021)

Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS
by: Xiaojiang Tian, et al.
Published: (2022)

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
by: Jeanne M. Schilder, et al.
Published: (2023)

Potential drug-drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan
by: Yusuke Kunimoto, et al.
Published: (2021)

Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System
by: Vera Martins, et al.
Published: (2023)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Lingqing Ding, et al.
Published: (2022)

Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system
by: Kaibin Niu, et al.
Published: (2024)

Factors associated with incomplete adherence to integrase strand transfer inhibitor-containing single-tablet regimen among Japanese people living with HIV
by: Yusuke Kunimoto, et al.
Published: (2024)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
by: Xiaoyin Bai, et al.
Published: (2021)

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)
by: Yiwen Bao, et al.
Published: (2024)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
by: Yankun Liang, et al.
Published: (2023)

Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System
by: Concetta Rafaniello, et al.
Published: (2021)

The differential effects of integrase strand transfer inhibitors and efavirenz on neuropsychiatric conditions and brain imaging in HIV-positive men who have sex with men
by: Yihui He, et al.
Published: (2024)

Analysis of Adverse Events of Cholinesterase Inhibitors and NMDA Receptor Antagonists on Arrhythmias Using the Japanese Adverse Drug Event Report Database
by: Shotaro Kobayashi, et al.
Published: (2023)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
by: Jing Huang, et al.
Published: (2020)

Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system
by: Jun Shen, et al.
Published: (2024)

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration's Adverse Event Reporting System from 2016 to 2021
by: Christine Learned, BA, et al.
Published: (2022)

Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database
by: Wakabayashi T, et al.
Published: (2020)

Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors
by: Prina Donga, et al.
Published: (2022)

Indications and adverse events of teriparatide: based on FDA adverse event reporting system (FAERS)
by: Ming-Tao Wen, et al.
Published: (2024)

Adverse events related to medication administration in a Taquari Valley hospital
by: Kellen Cristina Januário Benedetti Alves, et al.
Published: (2020)

Adverse Events Following Immunization
by: L.I. Chernyshova
Published: (2014)

Evaluating adverse events in databases
by: Katie Lovell, et al.
Published: (2023)

Adverse Events of DOACs in Children
by: Alessandra Bosch, et al.
Published: (2022)

Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system
by: Wei Wei, et al.
Published: (2023)

Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
by: Zoe Apalla, et al.
Published: (2021)

NURSES' KNOWLEDGE ABOUT ADVERSE EVENTS AND THE CHALLENGES OF REPORTING THESE EVENTS
by: Jamilly Santos Araujo, et al.
Published: (2016)

Gender differences in spontaneous adverse event reports associated with zolpidem in South Korea, 2015-2019
by: Kyung-In Joung
Published: (2023)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2022)

Vonoprazan-associated infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System
by: Mengling Ouyang, et al.
Published: (2024)

Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2024)

Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system
by: Xianglin Pan, et al.
Published: (2024)

Adverse event signal mining and severe adverse event influencing factor analysis of Lumateperone based on FAERS database
by: Yanjing Zhang, et al.
Published: (2024)

Postmarketing Surveillance of Full Spectrum Hemp Extract CBD Products: Reported Adverse Events and Serious Adverse Events
by: Colleen M. Kingsbury, et al.
Published: (2024)

Sarilumab‐induced cutaneous adverse event
by: Sayaka Sato, et al.
Published: (2022)

What Are Adverse Events in Mindfulness Meditation?
by: Dhanesh D. Binda BS, et al.
Published: (2022)

Hospital deaths and adverse events in Brazil
by: Pavão Ana Luiza B, et al.
Published: (2011)

Serious Neurological Adverse Events of Ceftriaxone
by: Clémence Lacroix, et al.
Published: (2021)